Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy, such as ifosfamide and vinorelbine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have refractory or relapsed Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: Ifosfamide; Isophosphamide mustard; Lenograstim; Vinblastine; Vinorelbine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed refractory or relapsed Hodgkin's lymphoma

• Mixed cellularity, not otherwise specified (NOS)

• Lymphocytic depletion, NOS

• Lymphocytic depletion, diffuse fibrosis

• Lymphocytic depletion, reticular

• Lymphocytic predominance, NOS

• Lymphocytic predominance, diffuse

• Lymphocytic predominance, nodular

• Hodgkin's paragranuloma NOS

• Hodgkin's granuloma

• Hodgkin's sarcoma

• Nodular sclerosis, NOS

• Nodular sclerosis, cellular phase

• Nodular sclerosis, lymphocytic predominance

• Nodular sclerosis, mixed cellularity

• Nodular sclerosis, lymphocytic depletion

• Other (type not specified)

• In first relapse

• Metastasis to bone marrow with granulocytopenia, anemia, and/or thrombocytopenia allowed

• Not enrolled on POG-9426 unless there is an extranodal site of recurrence

PATIENT CHARACTERISTICS:

Age:

• Under 30 at diagnosis

Performance status:

• Lansky 60-100% (for patients 16 years and under)

• Karnofsky 60-100% (for patients over 16 years)

Life expectancy:

• At least 2 months

Hematopoietic:

• See Disease Characteristics

• Absolute neutrophil count at least 1,000/mm^3

• Platelet count at least 75,000/mm^3 (transfusion independent)

Hepatic:

• Bilirubin no greater than 1.5 times normal

• SGOT or SGPT less than 2.5 times normal

Renal:

• Creatinine no greater than 1.5 times normal

• Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min

Cardiovascular:

• Shortening fraction at least 27% by echocardiogram OR

• Ejection fraction at least 50% by gated radionuclide

Other:

• No other concurrent serious illness

• No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or any other component of study drugs

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No concurrent immunomodulating agents

Chemotherapy:

• At least 2 weeks since prior chemotherapy (3 weeks for nitrosoureas) and recovered

• No other concurrent anticancer chemotherapy

Endocrine therapy:

• No concurrent steroids

• No concurrent corticosteroids (e.g., dexamethasone)

Radiotherapy:

• Recovered from prior radiotherapy

Surgery:

• Not specified